Narayana Hrudayalaya Ltd.
Narayana Hrudayalaya Ltd. operates in Hospital, part of the Healthcare sector. It booked ₹2,684 cr of revenue in its latest quarter (Q1 FY27) and kept 7.7% of sales as profit. It is the 7th largest of 9 Hospital companies we track, by market value.
| Segment | FY25 | FY26 | Share |
|---|---|---|---|
| Medical and healthcare related services | 5,609 | 7,689 | 99% → 95% |
| Others | 31 | 386 | 1% → 5% |
| Total | 5,640 | 8,074 |
From the company's consolidated segment filings (Ind AS 108). Margin is segment operating profit (before interest & tax) over segment revenue; reconciliation rows like inter-segment eliminations are excluded from the mix.
Healthier than 54% of companies in Healthcare, on all six measures of filed financials. Each measure is ranked against the 81–150 companies that reported it.
Measures financial condition, not whether to buy. Learn what this score means · How this is calculated
- RSI (14)
- 46
At close. Not part of the score.
How much profit it earns on the money it employs
How much it owes, and whether earnings cover the interest
Whether reported profit actually arrives as cash
Whether sales and profit have grown, and how steadily
What today's price implies, against our models or its peers
How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure
What if I invest in NH?
Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.
The slider starts at 15%, taken from this company's own free-cash-flow trend. That is history, not a forecast — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.
P/E, ROE, ROCE and margins are annualised from the latest quarter; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-09-17.
An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.
| Revenue from Operations | ₹2,684 cr |
| Other Income | ₹35 cr |
| Total Income | ₹2,719 cr |
| Cost of Materials | ₹0 cr |
| Purchases of Stock-in-Trade | ₹520 cr |
| Inventory Change (±) | ₹-6 cr |
| Employee Benefit Expense | ₹725 cr |
| Finance Costs | ₹87 cr |
| Depreciation & Amortisation | ₹156 cr |
| Other Expenses | ₹975 cr |
| Total Expenses | ₹2,457 cr |
| Profit before Tax | ₹262 cr |
| Tax Expense | ₹53 cr |
| Net Profit | ₹207 cr |
| Net margin on total income | 7.6% |
| Metric | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|
| Revenue | 2,151 cr | 2,594 cr | 2,684 cr |
| Total income | 2,174 cr | 2,623 cr | 2,719 cr |
| Expenses | 1,971 cr | 2,329 cr | 2,457 cr |
| Profit before tax | 152 cr | 294 cr | 262 cr |
| Tax | 22 cr | 64 cr | 53 cr |
| Net profit (owners' share) | 127 cr | 224 cr | 207 cr |
| Net margin (owners' share, on revenue) | 5.9% | 8.6% | 7.7% |
| EPS (₹) | 6.30 | 11.22 | 10.20 |
| Company | Price | Market cap | P/E | ROE | Net margin | 1-yr return |
|---|---|---|---|---|---|---|
| Apollo Hospitals Enterprise Limited | ₹8,769 | ₹1.26 L cr | 54.3 | 24.5% | 8.2% | — |
| Max Healthcare Institute Limited | ₹1,037 | ₹1.01 L cr | 78.1 | 12.0% | 13.6% | — |
| Manipal Health Enterprises Limited | ₹722 | ₹85,125 cr | 92.0 | — | 7.5% | — |
| Fortis Healthcare Limited | ₹886 | ₹66,897 cr | 62.8 | 10.8% | 10.5% | — |
| Aster DM Quality Care Limited | ₹761 | ₹39,412 cr | 613.4 | 1.4% | 1.2% | — |
| Global Health Limited | ₹1,424 | ₹38,273 cr | 60.2 | 16.0% | 12.2% | — |
| Narayana Hrudayalaya Ltd.this company | ₹1,869 | ₹38,187 cr | 45.8 | 18.3% | 7.7% | — |
| Krishna Institute of Medical Sciences Limited | ₹792 | ₹33,258 cr | 190.3 | 7.4% | 3.5% | — |
| Dr. Agarwal's Health Care Limited | ₹500 | ₹15,855 cr | 87.4 | 8.9% | 7.4% | — |
| Action | Detail | Ex-date |
|---|---|---|
| Dividend | ₹4.5 / share | 17 Jul 2026 |
| Dividend | ₹4.5 / share | 1 Aug 2025 |
| Dividend | ₹4 / share | 2 Aug 2024 |
| Dividend | ₹2.5 / share | 7 Jul 2023 |
| Dividend | ₹1 / share | 22 Aug 2022 |
| Dividend | ₹1 / share | 11 Mar 2020 |
A company cannot decide everything on its own. Things like a top executive’s pay, issuing new shares, or re-appointing a director have to be put to the people who own the company, and they vote — one vote per share. So whoever owns the most shares has the most say.
Every vote count above is taken from the result the company filed with the stock exchange, certified by an independent counter. To work out what would have happened without the promoters, we simply remove their votes and re-apply the same legal bar the proposal had to clear. Nothing here is an estimate or an opinion.
Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.
The company also transacted with 11 other related parties — subsidiaries, joint ventures, directors and others — that we could not match by name to the promoter list above. Some may still be connected to the family; we only count the ones the filings let us match with certainty.
Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.